Suppr超能文献

[肿瘤直径对宫颈癌患者治疗结果的影响]

[Influence of tumor diameter on treatment results in cervical cancer patients].

作者信息

Jońska-Gmyrek Joanna, Zółciak-Siwińska Agnieszka, Gmyrek Leszek, Staniaszek Jagna, Lindner Bogusław, Andrzejuk Jolanta

机构信息

Zakład Teleradioterapii, Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie w Warszawie, Polska.

出版信息

Ginekol Pol. 2012 Aug;83(8):576-80.

Abstract

UNLABELLED

The impact of the tumor size on treatment outcomes in cervical cancer patients remains a subject of controversy

OBJECTIVES

The assessment of prognostic value of pretreatment tumor size in cervical cancer patients.

MATERIALS AND METHODS

Patients of Maria Sklodowska - Curie Memorial Cancer Centre in Warsaw, treated between January 1996 and December 2000, were included into the retrospective study. 242 patients were diagnosed with a histologically confirmed squamous cell carcinoma and 42 with adenocarcinoma, FIGO staged IB-IVA, having undergone the clinical assessment and USG examination of the tumor treated with curative intent with surgery and/ or radiotherapy. The widest tumor diameter was adopted as the tumor size. In most cases of adenocarcinoma, the tumors were described as endocervical and the tumor measurement was connected with the risk of mistake, therefore, the analysis of the squamous cell cancer patients only was performed. A multivariate analysis of 242 patients with regard to overall survival (OS) and disease-free survival (DFS), depending on the selected clinico-pathological factors, was performed. The mean potential follow-up time for surviving patients was 50 months (range 8.7-62). The 5-year overall survival (OS) rate was 62%.

RESULTS

As the result of the multivariate analysis, the impact of FIGO stage (p=0.002), hemoglobin pretreatment concentration (p=0.031) and tumor size before treatment (p = 0.044) on OS, and FIGO stage (p=0.001), hemoglobin level before treatment (p=0.019) on DFS, was demonstrated.

CONCLUSIONS

Tumor diameter before treatment in squamous cell cervical cancer patients provides important prognostic information, regardless of other prognostic factors.

摘要

未标注

肿瘤大小对宫颈癌患者治疗结果的影响仍是一个有争议的话题。

目的

评估宫颈癌患者治疗前肿瘤大小的预后价值。

材料与方法

回顾性研究纳入了1996年1月至2000年12月期间在华沙玛丽亚·斯克洛多夫斯卡-居里纪念癌症中心接受治疗的患者。242例经组织学确诊为鳞状细胞癌,42例为腺癌,国际妇产科联盟(FIGO)分期为IB-IVA期,均接受了旨在治愈的手术和/或放疗,并进行了临床评估和超声检查。采用肿瘤最宽直径作为肿瘤大小。在大多数腺癌病例中,肿瘤被描述为宫颈管内的,且肿瘤测量存在误差风险,因此仅对鳞状细胞癌患者进行分析。根据所选临床病理因素,对242例患者的总生存期(OS)和无病生存期(DFS)进行多因素分析。存活患者的平均潜在随访时间为50个月(范围8.7-62个月)。5年总生存率为62%。

结果

多因素分析结果显示,FIGO分期(p=0.002)、治疗前血红蛋白浓度(p=0.031)和治疗前肿瘤大小(p = 0.044)对总生存期有影响,FIGO分期(p=0.001)、治疗前血红蛋白水平(p=0.019)对无病生存期有影响。

结论

鳞状细胞宫颈癌患者治疗前的肿瘤直径提供了重要的预后信息,无论其他预后因素如何。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验